Literature DB >> 15196886

Plasma retinol-binding protein: structure and interactions with retinol, retinoids, and transthyretin.

Giuseppe Zanotti1, Rodolfo Berni.   

Abstract

Retinol-binding protein (RBP) is the retinol-specific transport protein present in plasma. The available crystal structures of different forms of RBP have provided details of the interactions of this binding protein with retinol, retinoids, and transthyretin (TTR, one of the plasma carriers of thyroid hormones). The core of RBP is a beta-barrel, the cavity of which accommodates retinol, establishing with its buried portions apolar contacts. Instead, the retinol hydroxyl is near the protein surface, in the region of the entrance loops surrounding the opening of the binding cavity, and participates in polar interactions. The stability of the retinol-RBP complex appears to be further enhanced when holo-RBP is bound to TTR. Accordingly, the region of the entrance loops represents the contact area of RBP interacting with the TTR counterpart, such that the hydroxyl of the RBP-bound vitamin becomes fully buried in the holo-RBP-TTR complex. Limited protein conformational changes affecting the entrance loops, which lead to a decrease or loss of the binding affinity of RBP for TTR, have been demonstrated for apo-RBP and RBP in complex with retinoids modified in the area of the retinol hydroxyl. A relatively small number of amino acid residues of RBP, essentially confined to the region of the entrance loops, and of TTR appear to play a critical role in the formation of the RBP-TTR complex, as established by crystallographic studies, mutational analysis, and amino acid sequence analysis of phylogenetically distant RBPs and TTRs. Overall, the available evidence indicates the existence of a high degree of complementarity between RBP and TTR, the contact areas of which are highly sensitive to conformational changes and amino acid replacements.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15196886     DOI: 10.1016/S0083-6729(04)69010-8

Source DB:  PubMed          Journal:  Vitam Horm        ISSN: 0083-6729            Impact factor:   3.421


  48 in total

Review 1.  Retinoid pathway and cancer therapeutics.

Authors:  Nathan Bushue; Yu-Jui Yvonne Wan
Journal:  Adv Drug Deliv Rev       Date:  2010-08-03       Impact factor: 15.470

2.  Shortcomings in methodology complicate measurements of serum retinol binding protein (RBP4) in insulin-resistant human subjects.

Authors:  T E Graham; C J Wason; M Blüher; B B Kahn
Journal:  Diabetologia       Date:  2007-02-09       Impact factor: 10.122

3.  Synthesis and preliminary chemotherapeutic evaluation of the fully C-linked glucuronide of N-(4-hydroxyphenyl)retinamide.

Authors:  Joel R Walker; Galal Alshafie; Nirca Nieves; Jamie Ahrens; Margaret Clagett-Dame; Hussein Abou-Issa; Robert W Curley
Journal:  Bioorg Med Chem       Date:  2006-01-10       Impact factor: 3.641

4.  STRA6-catalyzed vitamin A influx, efflux, and exchange.

Authors:  Riki Kawaguchi; Ming Zhong; Miki Kassai; Mariam Ter-Stepanian; Hui Sun
Journal:  J Membr Biol       Date:  2012-07-20       Impact factor: 1.843

Review 5.  Membrane receptors and transporters involved in the function and transport of vitamin A and its derivatives.

Authors:  Hui Sun
Journal:  Biochim Biophys Acta       Date:  2011-06-17

Review 6.  The membrane receptor for plasma retinol-binding protein, a new type of cell-surface receptor.

Authors:  Hui Sun; Riki Kawaguchi
Journal:  Int Rev Cell Mol Biol       Date:  2011       Impact factor: 6.813

Review 7.  Current and future treatment of amyloid diseases.

Authors:  M Ankarcrona; B Winblad; C Monteiro; C Fearns; E T Powers; J Johansson; G T Westermark; J Presto; B-G Ericzon; J W Kelly
Journal:  J Intern Med       Date:  2016-05-10       Impact factor: 8.989

Review 8.  The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug.

Authors:  Steven M Johnson; Stephen Connelly; Colleen Fearns; Evan T Powers; Jeffery W Kelly
Journal:  J Mol Biol       Date:  2012-01-05       Impact factor: 5.469

Review 9.  Headway and hurdles in the clinical development of dietary phytochemicals for cancer therapy and prevention: lessons learned from vitamin A derivatives.

Authors:  Christina Y Yim; Pingping Mao; Michael J Spinella
Journal:  AAPS J       Date:  2014-01-16       Impact factor: 4.009

10.  An essential ligand-binding domain in the membrane receptor for retinol-binding protein revealed by large-scale mutagenesis and a human polymorphism.

Authors:  Riki Kawaguchi; Jiamei Yu; Patrick Wiita; Jane Honda; Hui Sun
Journal:  J Biol Chem       Date:  2008-04-03       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.